CHICAGO, June 17 The Female Health Company(Amex: FHC) announced it has received a bid award for two million FC femalecondoms from the New York City Department of Health and Mental Hygiene. TheCompany expects shipments to begin immediately, at the direction of the HealthDepartment. The terms of the award allow the City to increase purchasequantities beyond the two million units, should they so desire.
O.B. Parrish, Chairman and CEO of the Female Health Company, said, "Weapplaud Mayor Michael Bloomberg and the City of New York for recognizing theHIV/AIDS risk to women and providing the much-needed education andprotection."
About The Female Health Company, Inc.
The Female Health Company, based in Chicago, Illinois, manufactures andmarkets the FC Female Condom(R), which is primarily distributed by publichealth organizations and donor groups in over 90 developing countries aroundthe world. World-wide, the Female Condom is available in various programs in108 countries. The Company owns certain worldwide rights to the FC FemaleCondom(R), including patents that have been issued in the United States,United Kingdom, Japan, France, Italy, Germany, Spain, the European PatentConvention, the People's Republic of China, Canada, South Korea and Australia.FC Female Condom(R) is the only available FDA-approved product controlled by awoman that offers dual protection against sexually transmitted diseases,including HIV/AIDS, and unintended pregnancy.
For more information about the Female Health Company, visit the Company'sweb site at http://www.femalehealth.com or http://www.femalecondom.org.
"Safe Harbor" statement under the Private Securities Litigation Reform Actof 1995:
The statements in this release which are not historical fact are"forward-looking statements" as that term is defined in the Private SecuritiesLitigation Reform Act of 1995. Forward-looking statements in this release maybe identified by the use of forward-looking words or phrases such as"anticipate," "believe," "could," "expect," "intend," "may," "planned,""potential," "should," "will," "would" or the negative of those terms or otherwords of similar meaning. These statements are based upon the Company'scurrent plans and strategies, and reflect the Company's current assessment ofthe risks and uncertainties related to its business, and are made as of thedate of this release. The Company assumes no obligation to update anyforward-looking statements contained in this release as a result of newinformation or future events, developments or circumstances. Suchforward-looking statements are inherently subject to known and unknown risksand uncertainties. The Company's actual results and future developments coulddiffer materially from the results or developments expressed in, or impliedby, these forward-looking statements. Factors that may cause actual resultsto differ materially from those contemplated by such forward-lookingstatements include, but are not limited to, the following: product demand andmarket acceptance; competition in the Company's markets and the risk of newcompetitors and new competitive product introductions; the Company's relianceon its international partners in the consumer sector and on the level ofspending on the female condom by country governments, global donors and otherpublic health organizations in the global public sector; the economic andbusiness environment and the impact of government pressures; risks involved indoing business on an international level, including currency risks, regulatoryrequirements, political risks, export restrictions and other trade barriers;the Company's production capacity; efficiency and supply constraints; andother risks detailed in the Company's press releases, shareholdercommunication and Securities and Exchange Commission filings, including theCompany's Form 10-KSB for the fiscal year ended September 30, 2007. A